# *For BIS Use Only*

BUREAU OF INDIAN STANDARDS

AGENDA

# Fourth meeting of Homoeopathy Sectional Committee (AYD-07)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Name of the Committee** | **Meeting Number** | **Day** | **Date** | **Time** | **Venue** |
| **Homoeopathy Sectional Committee AYD-07** | **4** | **Tuesday** | **26.03.2024** | **10.30 am** | **Samvaad (Green Room),**  **Manak Bhawan, BIS, Delhi**  **(Hybrid Mode)** |
| **CHAIRPERSON:** **Dr Raj K. Manchanda** | | | **MEMBER SECRETARY:** **Dr. Kumar Vivekanand** | | |

# ITEM 0 GENERAL

**0.1 Welcome**

# 0.2 Opening Remarks by the Chairperson, AYD-07

# ITEM 1 CONFIRMATION OF MINUTES OF THE LAST MEETING

The minutes of the 3rd Homoeopathy Sectional Committee (AYD-07) meeting held on 29.12.2023 duly approved by the Chairperson were circulated to committee members through BIS module**.** No comments on the accuracy of recording were received.

***The Committee may kindly CONFIRM the minutes as circulated.***

**ITEM 2 SCOPE, ACTIVITIES AND COMPOSITION**

**2.1 Scope and activities (Program of Work) of the Committee**

The scope and activities of the AYD-07 is embedded below as **Annex I:**



***The Committee may kindly note.***

**2.2 Composition of the Sectional Committee**

**2.2.1** The present composition of the AYD 07 along with the attendance record of last three meeting is embedded below as **Annex II.** Composition of the Expert Panel that come under the purview of AYD7 is also embedded below as **Annex III.**

**** ****

***The Committee may kindly deliberate.***

**2.2.2** As decided in the 3rd meeting, reminders have been sent to the following organizations for nominations in the Homoeopathy Sectional Committee:

1. Central Government Health Scheme (CGHS), New Delhi
2. All India Institute of Medical Sciences (AIIMS), Dept. of Pharmacology, New Delhi
3. National Medicinal Plants Board (NMPB), Ministry of AYUSH, New Delhi
4. Synergy Homeopathic, 201, Dinar, 20 Station Road, Santacruz (W), Mumbai, Maharashtra
5. AYUSHEXCIL (Ayush Export Promotion Council), New Delhi

No nominations has been received so far.

***The Committee may kindly deliberate.***

**2.2.3** As decided in the 2nd meeting, nominations of Ms. Anamika Kotiya, Pharmacist, from Dr DP Rastogi Central Research Institute for Homoeopathy, Noida has been received as Young Professional.

***The Committee may kindly note.***

**2.2.4** Nomination of Dr. Rachna Goenka, currently working at Midnapore Homoepathic Medical College and Hospital (Govt. of West Bengal) in the department of Homoeopathic Pharmacy has been received as a member on **Personal** **capacity**. She has approximately 30 years of teaching experience including 20 years in the field of Homoeopathy. Her resume is embedded below as **Annex IV:**



***The Committee may kindly deliberate.***

# ITEM 3 DRAFT INDIAN STANDARDS COMPLETED WC FOR FINALIZATION

**3.1 Doc. AYD 07 (23330) WC Draft Indian Standard - Glossary of Homoeopathy Terminology- Standardized Terminology for Commonly Used Terms Related to Homoeopathy**

Comments on the draft alongwith inputs from the Panel is embedded below as **Annex V.** The modified draft on the subject as submitted by the Panel is also embedded below as **Annex VI.**

 

***The Committee may kindly deliberate.***

**3.2 Doc. AYD 07 (23521) WC Draft Indian Standard – Plastic Containers and Closures for Manufacturing Packaging Dispensing of Homoeopathic Medicine - Specification**

Comments on the draft along with inputs from the Panel are given below:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sl No.** | **Clause/Sub- clause/ para/table/fig. No. commented** | **Commentator/ Organization/ Abbreviation** | **Type of Comments** | **Justification** | **Proposed change** | **Observation of Panel/BIS** |
|  | 4.1.3/ Para 4 | Bakson Drugs and Pharmaceuticals | Technical |  | Plastic jars are used in Homeopathy for the dispensing and sale of Homeopathic tablets. | Accepted and modified |
|  | 5.2 (B.1)/ Para 3 | Bakson Drugs and Pharmaceuticals | Technical | The solution should be (Solution S5) for Ethanol Extraction, instead of S2. As alcohol extration/ solution mentioned on page 9 (table 1) is S5. | Solution S5 (Ethanol Extraction): Place 10 g of the sample in a round bottom flask. Add 100.0 ml of ethanol (95 %) and reflux at 500 for 5 hours. Allow to cool and decant the solution. Note: Use solution S5 within 4 hours of its preparation | Accepted and modified |
|  | 5.2 (B.1.3)/ Para 1 | Bakson Drugs and Pharmaceuticals | Technical | The solution should be (**Solution S5**) for Ethanol Extraction, instead of S2.  As alcohol extration/ solution mentioned on page 9 **(table 1**) is **S5**. | B.1.3. Absorbance of solution S5:  In the visible range (400 nm to 800 nm): absorbance should be not more than 0.05. | Accepted and modified |
|  | 5.1.1.1/ Para 1 | Bakson Drugs and Pharmaceuticals | Technical | No need to write USP along with High-Density Polyethylene RS.  only we can use only High-Density Polyethylene RS | The specimen exhibits an absorption spectrum that is substantially equivalent to that of High-Density Polyethylene RS. | Accepted and modified |
|  | 5.1.1 & 5.1.1/ Para 1 | Bakson Drugs and Pharmaceuticals | Technical | Delete the word container from heading (HDPE container) & (LDPE container). As these method are for containers and closures both. | 5.1.1 HDPE  5.1.2 LDPE | Accepted and modified |
|  | 5.1.2.1/ Para 1 | Bakson Drugs and Pharmaceuticals | Technical | No need to write USP along with Low-Density Polyethylene RS.  only we can use only Low-Density Polyethylene RS | The specimen exhibits an absorption spectrum that is substantially equivalent to that of the Low-Density Polyethylene RS. | Accepted and modified |
|  | 5.2 & 5.3 | Bakson Drugs and Pharmaceuticals | Editorial | No need to wrtie Containers/closures along with Polyethylene terephthalate (pet) containers/ closures and polypropylene containers (pp) containers/ closures All headings should be same for Plastic type in the monograph. | 5.2 POLYETHYLENE TEREPHTHALATE (PET)  5.3 POLYPROPYLENE (PP) | Accepted and modified |
|  | 5.3 (A)- Test 1/ Para 5 | Bakson Drugs and Pharmaceuticals | Editorial | No need to write USP along with Homopolymer Polypropylene RS.  we can use only Homopolymer Polypropylene RS. | Acceptance criteria: The specimen exhibits an absorption spectrum that is substantially equivalent to that of the Homopolymer Polypropylene RS. | Accepted and modified |
|  | 8.2/ Para 1 | Bakson Drugs and Pharmaceuticals | Technical | Need to add "wherever required" for sterilization of containers and closures . | 8.2 The Phials/Droppers/Stoppers/Caps shall be packed by using Thermoform or Automatic packaging machine after sterilizing (werever required) in sterilization plant using Ethylene oxide or Gamma radiations. | Accepted and modified |
|  | 5 | CDSCO | General | When the opening paragraph mentions that Homoeopathic pharmaceutical industries shall ensure that the containers procured by them are in compliance with the below testing parameters. A certificate of analysis with these parameters from the plastic manufacturing companies can be accepted for this purpose. In view of above detailed testing methods is not required in this document. The testing parameters for plastic is not exclusive for homoeopathic industry. | It is suggested that a tabulated reference may be included for the type of plastic and testing requirement standard number. Please refer the Plastics-Methods of testing WC documents of PCD 27. | Not accepted as we are aiming to prepare a comprehensive draft and many a times vendors do give correct COA (certificate of analysis) |

The draft on the subject have been modified accordingly and embedded below as **Annex VII**:



***The Committee may kindly deliberate.***

**3.3 Doc. AYD 07 (23564) WC Draft Indian Standard - Glass Containers and Closures for Packaging and Dispensing of Homoeopathic Medicine – Specification**

Comments on the draft along with inputs from the Panel are given below:

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Sl No.** | **Clause/Sub- clause/ para/table/fig.**  **No. commented** | **Actual Clause /paragraph** | **Commentator/ Organization/ Abbreviation** | **Type of Comments (General/Editorial/ Technical)** | **Justification** | **Proposed change** | **Observation of the Panel/BIS** |
|  | 4.9/ Para 1/ | 4.10 & 4.11 | Dr. Willmar Schwabe India Private Limited | Technical | Considering that purified water is used for the final rinse and proper drainage is ensured, the need for drying is not required for many products. Thus, this point can be modified as needed. | After the final rinse, bottles shall be air dried or vacuum dried properly if required depending on the product type. | Accepted and modified |
|  | 4.1/ Para 1 | 4.1 | Dr. Willmar Schwabe India Private Limited | Technical | The recommendation is to choose containers based on glass suitability determined by hydrolytic resistance tests and stability data for pharmaceutical products. Nevertheless, it might be more suitable to specify standards that align with the product type, be it solid or liquid. | 4.1 Material and Workmanship – Pharmaceutical containers shall be prepared by using either borosilicate (neutral) glass or soda-lime-silica glass, of Type I, II or III glass material, clear or amber colored, and have smooth surface without cracks, pinholes, or sharp edges as per USP 660. The selection of containers should be based on the suitability of the glass type for pharmaceutical products, based on the tests for hydrolytic resistance and stability test data. Generally, type II is recommended for liquid products and type III is for solid products. | **Generally, type II is recommended for liquid products and type III is for solid products**. This line altogether can be deleted as we are using liquids also in type 3 and it all depends upon product stability |
|  | 4.7/ Para 1 | 4.7 | Dr. Willmar Schwabe India Private Limited | Technical | This standard is actually for the homeopathic manufacturing firm, whereas this corresponds to the glass manufacturing company. Hence we suggest making a change. | It is imperative for the homeopathic manufacturing company to ensure that glass containers are manufactured in compliance with good manufacturing practices (GMP). | Accepted and modified |
|  | 4.9/ 1 | 4.10& 4.11 | Dr. Willmar Schwabe India Private Limited | Technical | Considering that purified water is used for the final rinse and proper drainage is ensured, the need for drying is not required for many products. Thus, this point can be modified as needed. | Upon completion of the final rinse, it is essential to properly air dry or vacuum dry the bottles. | After the final rinse, bottles shall be air dried or vacuum dried properly if required depending on the product type.  Already commented in point 1 above |
|  | 4.1/ 1 | 4.1 | Dr. Willmar Schwabe India Private Limited | Technical | The recommendation is to choose containers based on glass suitability determined by hydrolytic resistance tests and stability data for pharmaceutical products. Nevertheless, it might be more suitable to specify standards that align with the product type, be it solid or liquid. | 4.1 Material and Workmanship – Pharmaceutical containers shall be prepared by using either borosilicate (neutral) glass or soda-lime-silica glass, of Type I, II or III glass material, clear or amber colored, and have smooth surface without cracks, pinholes, or sharp edges as per USP 660. The selection of containers should be based on the suitability of the glass type for pharmaceutical products, based on the tests for hydrolytic resistance and stability test data. Generally, type II is recommended for liquid products and type III is for solid products. | **Generally, type II is recommended for liquid products and type III is for solid products**. This line altogether can be deleted as we are using liquids also in type 3 and it all depends upon product stability. Modified accordingly. |
|  | 5 | 4.8 | Dr. Willmar Schwabe India Private Limited | General | It would be better if the brackets are removed and the unit mL is specified before the quantities. | One example of 5.1.1 is given below:  5.1.1 Capacity: The nominal capacities of the containers shall be (in mL):  1.6, 3, 6 | Not traced in document |
|  | 5.2.1/ Para 1 | 4.8 | Dr. Willmar Schwabe India Private Limited | Technical | 1. 20 mL is also used in homoeopathy commonly, especially the imported products.  2. Large containers are also used especially in veterinary segment. | 5.2 Glass Bottles  5.2.1 Capacity: The nominal capacity of the container shall be (in mL):  (10, 12, 15, 20, 30, 45, 60, 100, 115, 125, 200, 450, 500, 750, 1000 and in multiples of 1000. | Accepted and modified |
|  | 6 | 5 (para 1) | Dr. Willmar Schwabe India Private Limited | Technical | It may not be possible to conduct the tests by homoeopathic manufacturers. Hence a CoA by the glass manufacturer may also be accepted. | 6. TESTING  Homoeopathic manufacturer shall ensure the compliance of below tests. A certificate of analysis by a glass manufacturer may also be accepted.  6.1 Hydrolytic Resistance of Glass Containers: | It is already written so no change required here |
|  | 6/6.1.1/ Para | 5/5.1.1/para  Apparatus :  Autoclave - Line2 & line 6 | Medisynth Chemicals Private Limited | General | Page 5- Clause 6/6.1.1 Glass Grains Test (USP 660):  Paragraph 1, Line 2 : 1°  As per SI unit, the symbol for degree celcius is " °C".  Paragraph 1, Line 2 : 121 ± 1°  Paragraph 1, Line 6 : purified Water | 1° C  121 ± 1° C and 15 lbs pressure  Purified Water | Accepted and modified |
|  | 6/6.1.1/ Para 1 | 5/5.1.1  Bullet 6 | Medisynth Chemicals Private Limited | General | Page 5 - Clause 6/6.1.1 Glass Grains Test (USP 660)  Bullet 6: Weighing bottles & stoppers  ( Write "&" in words) | Weighing bottles and stoppers | Accepted and modified |
|  | 6/6.1.1/ Para 3 | 5/5.1.1  Sample preparation: bullet 3, line 12 | Medisynth Chemicals Private Limited | General | Page 6 - Clause 6/6.1.1 Sample Preparation  Line 12: heating at 140° | heating at 140° C | Accepted and modified |
|  | 6/6.1.1/ Para 1 | 5/5.1.1  Operations: s.no. 3,4,5,6,7 | Medisynth Chemicals Private Limited | Editorial | Page 7 - Clause 6/6.1.1 Operations  Points: 3,4,5,6  Units for temperature not mentioned | Mention "° C", wherever applicable | Accepted and modified |
|  | 6/6.1.2/ 2 | 5/ 5.1.2/ para 3/ line 3 | Medisynth Chemicals Private Limited | General | Page 8 - Clause 6/6.1.2 Determination of the filling volume  Line: For ampuls  Typographical error | For ampoules | Accepted and modified |
|  | 6/6.1.2/ Para 1 | 5/ 5.1.2  Filling and heating : line 8 | Medisynth Chemicals Private Limited | General | Page 9 - Clause 6/6.1.2 Method, Filling and Heating  Line 2: 121 ± 1°  Mention the unit for temperature and also mention the pressure | 121 ± 1° C, 15 lbs pressure | Accepted and modified |
|  | 6/6.5/ Para 1 | 5.5/ para 4/ line 5 | Medisynth Chemicals Private Limited | General | Page 11 - Clause 6/6.5 Evaluatio of Inner Surface Durability of Glass Container  Line 5: if a product will be stored at 5° and accelrated conditions are 30°, then testing should ocuur at 30°  Mention the unit of temperature | if a product will be stored at 5°C and accelrated conditions are 30°C, then testing should ocuur at 30°C | Accepted and modified |
|  | 6/6.1.2/ Para 4 | 5/ 5.1.2  Method  Cleaning / line 5 | Medisynth Chemicals Private Limited | General | Page 8 - Clause 6/6.1.2 Method, Cleaning  Line 5 : Air oven about 40° | Air oven about 40 °C | Accepted and modified |
|  | Foreword/ Para 1 and 2 | Foreword/ Para 1 | Dr. Dharam Prakash Rastogi Central Research Institute of Homoeopathy | General | Begning word is vague in the context of glass and this has to be supported with the importance of the invention of glass manufaturing in medicine  General considerations to provide quality in manufacturing not given in second paragraph | After first line ends, following line is to be added.  "The invention of making of glass and its use in the field of medicine for storing and dispensing is significant contribution of science to humanity".  Second paragraph:  "To gain the optimum quality in the manufacturing process, folllowing should be given due consideration:  Testing  Functionality test  Analytical methods for screening studies | Not actually required |
|  | Foreword/ Para all paragraphs |  | Dr. D P Rastogi Central Research Institute of Homoeopathy, Noida | General | relevant points in foreword | given in attachment file | There was no attachment not understandable. Not changed. |
|  | Foreword/ Para 3 | foreword | Dr. Anjali Chatterjee Regional Research Institute of Homoeopathy, Kolkata | Editorial | Homoeopathy spelling is different in the same paragraph | In view of the present scenario of Homoeopathy where the globalization of the Homoeopathic products takes place; there is a need for standards which should be followed by Homoeopathic industries regarding their product to facilitate their product acceptance among consumers. | Accepted and modified |
|  | Para 3 | Foreword/ para 3 | Homoeopathic Pharmaceutical Association of India | Editorial | Paragraph 3: line 3  Should be followed by Homeopathic industry instead of industries. | In view of the present scenario of Homeopathy where the globalisation of the Homeopathic products take place, there is a need for standards whihc should be followed by Homeopathic industry regarding their product to facilitate their product acceptance among consumers. | Accepted and modified |
|  | 4.7 | 4.7 | Homoeopathic Pharmaceutical Association of India | General | Glass manufacturer to be GMP or have any certifications required for assuring high quality and upto standard glass can be captured here. |  | GMP must be there this line should not be changed |
|  | 4.11 | 4.11 | Homoeopathic Pharmaceutical Association of India | Editorial | Properly is not defined and not a recommended word in standards or procedures.  So recommended to change to a more suitable and well defining word, like as per validated procedure. | After the final rinse, containers shall be air dried or vaccum dried as per a validated procedure. | Not required line is ok |

The draft on the subject have been modified accordingly and embedded below as **Annex VIII**:



***The Committee may kindly deliberate.***

**3.4 Doc. AYD 07 (24416) WC Draft Indian Standard - Millefolium (Achillea millefolium l.) whole plant for use in homeopathic medicine — Specification**

The Comments on the draft has been resolved by the Panel and is embedded below as **Annex IX.** Accordingly, the modified draft on the subject is embedded below as **Annex X.**

**** ****

For better clarity of the standards, it is suggested to have 02 separate standards (01 for raw drug which may be used by others also and 01 for homoeopathy mother tincture) as “**Millefolium (Achillea millefolium l.) whole plant for use in traditional medicine — Specification”** and **“Millefolium (Achillea millefolium l.) mother tincture for use in homeopathic medicine- specification)”**  respectively**.**

***The Committee may kindly deliberate.***

**3.5 Doc. AYD 07 (23908) WC Draft Indian Standard - Non-medicated Homoeopathic Tablets – Specification**

The Comments on the draft has been resolved by the Panel and is embedded below as **Annex XI.** Accordingly, the modified draft on the subject is embedded below as **Annex XII.**

 

***The Committee may kindly deliberate.***

# ITEM 4 DRAFT INDIAN STANDARDS UNDER WIDE CIRCULATION

The following items/drafts Indian standards have been circulated for wide circulation with 60 days commenting period, with last date of comments as:

|  |  |  |  |
| --- | --- | --- | --- |
| **S. No.** | **Doc No.** | **Title of the Draft Standard/WC-Draft** | **Circulation completion date** |
|  | [**AYD/07/2**](https://www.services.bis.gov.in/php/BIS_2.0/StandardsFormulationV2/Upload3.php?ID=eDI0Vm1VYmlmRVozdTNiVW91WURidz09)**4468** | **Globules for use in Homoeopathy Specification** | 24th March 2024 |
|  | [**AYD/07/2**](https://www.services.bis.gov.in/php/BIS_2.0/StandardsFormulationV2/Upload3.php?ID=eDI0Vm1VYmlmRVozdTNiVW91WURidz09)**4851** | **Withania somnifera mother tincture for use in homeopathic medicine- specification** | 5th May 2024 |

***The Committee may kindly note.***

# ITEM 5 APPROVAL OF DRAFT STANDARDS FOR WIDE CIRCULATION

The following items/drafts have been circulated among members of the Sectional Committee:

|  |  |  |  |
| --- | --- | --- | --- |
| **S. No.** | **Doc No.** | **Title of the Draft Standard/P-Draft** | **Circulation completion date** |
| **1.** | [**AYD/07/24934**](https://www.services.bis.gov.in/php/BIS_2.0/StandardsFormulationV2/Upload3.php?ID=eDI0Vm1VYmlmRVozdTNiVW91WURidz09) | **Alfalfa (medicago sativa L) for use in homeopathic medicine- specification** | 9th March 2024 |

The Comments on the draft has been resolved by the Panel and is embedded below as **Annex XIII.**

For better clarity of the standards, it is suggested to have 02 separate standards (01 for raw drug and 01 for mother tincture). Accordingly, the modified draft on the raw drug and mother tincture is embedded separately below as **Annex XIV (Alfalfa, whole plant excluding roots for use in traditional medicine — Specification)** and **Annex XV (Alfalfa (medicago sativa L) mother tincture for use in homeopathic medicine- specification).**

  

The Committee may kindly deliberate and approve the draft for wide circulation for a period of two months.

***The Committee may kindly consider.***

# ITEM 6 DRAFTS UNDER PREPARATION

During the first and second Sectional committee meeting held on 17th May & 05th October 2023, the following panels were constituted for the preparation of P drafts. Drafts under preparation by the panels are given below:

|  |  |  |  |
| --- | --- | --- | --- |
| **S. No.** | **Panel**  **Number** | **Subject** | **Status** |
|  | AYD07/P1 | Plant origin raw materials and Methods of preparations of Homoeopathic Mother tinctures, including finished product. | Following drafts on plant drugs specifications for use in homoeopathy from the list of frequently used drugs are under preparation:   * Gymnema Sylvestre (Raw drug and Mother Tincture) Specification for use in Homoeopathy * Hydrocotyle Asiatica (Raw drug and Mother Tincture) Specification for use in Homoeopathy * Jaborandi (Raw drug and Mother Tincture) Specification for use in Homoeopathy * Echinacea Angustifolia (Raw drug and Mother Tincture) Specification for use in Homoeopathy * Sabal Serrulata (Raw drug and Mother Tincture) Specification for use in Homoeopathy |
|  | AYD07/P2 | Homoeopathic Terminology and Abbreviations of medicines | Abbreviations of homoeopathic medicines is under preparation. |
|  | AYD07/P3 | Generic formulations | No P draft prepared as of now. However, road map has been discussed for formulations in Homoeopathy which can be taken up for standardization work. |
|  | AYD07/P4 | Potentization process, machine/ devices, used/ can be used in Homoeopathy | P draft titled ''Standardization for the process of potentization'' is under preparation. |
|  | AYD07/P5 | Glass/plastic bottles/phials, stoppers for wholesale/ retail packaging and dispensing | P-drafts on Sugar of Milk and Excipients are under preparation. |
|  | AYD07/P6 | Homoeopathic Software | No P draft prepared as of now. However, road map has been discussed for formulations draft standard. |

***The Committee may kindly note and deliberate.***

# ITEM 7 NEW WORK ITEM PROPOSALS FOR STANDARDIZATION

**7.1 Herbs which have not been addressed by the pharmacopoeia commission or are absent in published pharmacopeias**

Following our recent meeting with standardization cells of industry, dated 14.02.2024, we received a particularly interesting proposal regarding the development of standards for unique and unstandardized herbs. These herbs, currently absent in official pharmacopoeias published by the PCIMH, and may hold significant therapeutic potential. This proposal aims to establish guidelines and specifications for these unique herbs used in homeopathic practices. List is as under:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1. Anatherum   muricatum | 1. Boerhaavia   repens | 1. Bryophyllum calycinum | 1. Chaparro amargoso | 1. Cystisus   scoparius |
| 1. Ficus venosa | 1. Gentiana   chirata | 1. Ocimum radix | 1. Origanum   majorana | 1. Saussurea   lappa |

***The Committee may kindly deliberate.***

**7.2 Standardization related to Ayush Hospitals and wellness centres**

As suggested by the Ayush Division Council in its 2nd meeting held on 24.01.2024 in item no. 6.2, the Committee may undertake standardization activity related to Ayush Hospitals and wellness centres in Homoeopathic stream. The Minutes of the 2nd meeting of Ayush Division Council is embedded below as **Annex XVI.**



***The Committee may kindly deliberate.***

**7.3 Standard Treatment Guideline (Homoeopathic Stream)**

Following a meeting of BIS with Ministry of Ayush, it is suggested to develop an Indian Standard for Standard Treatment Guidelines related to Homoeopathy, which may signify a potential step towards establishing nationally recognized guidelines for homoeopathic treatment in India.

***The Committee may kindly deliberate.***

**7.4 The committee may also suggest any other new areas for standards formulation and suggest experts for the same.**

***The Committee may kindly deliberate.***

# ITEM 8 TECHNICAL ISSUES

Ayush Division Council in its 2nd meeting in item no. 6.4, decided to align the Standards on Single herbs with “One herb one standard” documents under development in Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM & H). The Council advised the AYD technical committees to give consideration to the same.

***The Committee may kindly deliberate.***

# ITEM 9 DATE AND PLACE OF THE NEXT MEETING

BIS has formulated a meeting calendar for the next one year and it has been proposed to conduct a meeting of each Sectional Committee on a quarterly basis. Accordingly, the next meeting of the committee may be organized during April-June 2024 in consultation with the Chairman.

***The Committee may kindly note.***

# ITEM 10 ANY OTHER BUSINESS

# The Committee may discuss any other item, with the permission of the chair.

# \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*